Sagent Pharmaceuticals Inc said on Thursday that its Canadian subsidiary Omega Laboratories Limited has received approval for the manufacturing of US Food and Drug Administration (FDA)-approved products under the FDA's initial Establishment Inspection Report.
Based in Montreal, the Omega site is approved to manufacture small molecule products. It becomes the second FDA-approved facility in the Nichi-Iko Group network.
The Omega site reportedly provides Sagent with up to 30 million vials of annual internal manufacturing capacity, significantly expanding its ability to deliver products consistently to patients across the US.
Sagent Pharmaceuticals is focused on developing, manufacturing, sourcing and marketing pharmaceutical products for the North American market. It is part of Nichi-Iko Group Company, one of the largest generic drug manufacturers in Japan by sales.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT